Pilot Text Message for Influenza Vaccination

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Melissa Stockwell, MD, MPH, Columbia University
ClinicalTrials.gov Identifier:
First received: December 30, 2012
Last updated: September 6, 2013
Last verified: September 2013

Influenza is an important and potentially preventable cause of morbidity and mortality, yet only 46% of U.S. adults were vaccinated by the end of the 2011-12 influenza season despite influenza vaccination being widely recommended, effective, and safe. Influenza vaccination rates are even lower in racial/ethnic minority groups. In order to address the problem of low influenza vaccination rates in minority adults, we plan to build on the well-accepted practice of immunization recall-reminders and the emerging practice of using text message to pilot the feasibility of using text messaging to improve influenza vaccination coverage rates in a low health literacy, largely minority, publicly insured adult population.

Condition Intervention
Behavioral: text message

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Health Services Research
Official Title: Pilot Study of Text Message Reminders for Flu Vaccine For Adults

Resource links provided by NLM:

Further study details as provided by Columbia University:

Primary Outcome Measures:
  • Receipt of an influenza vaccine dose [ Time Frame: March 31, 2013 ] [ Designated as safety issue: No ]
    Proportion of individuals in each group receiving an influenza dose by the end of the influenza season

Estimated Enrollment: 1000
Study Start Date: January 2013
Estimated Study Completion Date: December 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: text message
receipt of text message
Behavioral: text message
No Intervention: usual care
usual care


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • > or = 18 years of age,
  • at least one visit to the AIM clinic during the previous year
  • a cell phone number in the registration system
  • fluent in English or Spanish. Exclusion criteria

Exclusion Criteria:

  • Receipt of influenza vaccination during the 2012-2013 influenza season prior to randomization.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01761734

United States, New York
Columbia University
New York, New York, United States, 10032
Sponsors and Collaborators
Columbia University
Principal Investigator: Melissa Stockwell, MD MPH Columbia University
Principal Investigator: Steven Shea, MD MS Columbia University
Principal Investigator: Jessica Singer, MD MPH Columbia University
  More Information

No publications provided

Responsible Party: Melissa Stockwell, MD, MPH, Assistant Professor of Pediatrics and Population and Family Health, Columbia University
ClinicalTrials.gov Identifier: NCT01761734     History of Changes
Other Study ID Numbers: AAAK5058
Study First Received: December 30, 2012
Last Updated: September 6, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Columbia University:
Influenza vaccination

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on April 17, 2014